24 stories from 7 sources
Supporting Articles
The United States is experiencing its worst measles outbreak since 1991, with the CDC recording a measles death and Pennsylvania officials reporting four deaths among unvaccinated people in recent weeks. The outbreak underscores the consequences of declining protection against a highly contagious disease.
7:52 AMStat News
Jewel Mullen recounts nearly dying from measles as a child in 1961 and describes her alarm at the disease's return. Writing as a physician, she connects that personal experience to the current erosion of confidence in measles vaccination.
4:30 AMStat News
FDA commissioner nominee Heidi Overton faced questions from senators about vaccines, abortion, and vapes during her confirmation hearing. She largely avoided revealing firm positions on the most politically contentious issues.
4:21 PMStat News
Heidi Overton, President Trump's nominee to lead the FDA, built her career from a medical background in rural New Mexico to a national regulatory role. The profile examines her training, experience, and path to the nomination.
4:30 AMStat News
Heidi Overton, President Trump's nominee to lead the FDA, is scheduled to answer questions from senators during her confirmation hearing. The hearing will examine her qualifications, policy views, and approach to running the agency.
4:30 AMStat News
The report examines the expected start of Heidi Overton's tenure at the FDA and includes reporting from Shanghai. It combines U.S. regulatory developments with international healthcare and policy observations.
3:30 PMStat News
At a Senate hearing, FDA commissioner nominee Heidi Overton is expected to emphasize speed and efficiency as the agency competes with China. The hearing places regulatory performance and biotechnology competition at the center of her case for leading the agency.
9:21 AMStat News
AI tools that identify patients' secondary medical conditions added nearly $1 billion in costs for Blue Cross Blue Shield insurers over two years, according to a study from the Blue Cross Blue Shield Association. The findings focus on the financial impact of AI-assisted medical coding in provider claims.
2:39 PMPYMNTS
Researchers found that mammalian cells can produce the essential amino acid cysteine even after disabling pathways previously thought necessary for that process. The backup mechanism may help cancer cells survive treatment, making it a possible target for therapies designed to leave tumors unable to recover.
9:55 PMScienceDaily
Kyverna Therapeutics reported new data suggesting that many patients who received its cell therapy for an autoimmune disease remained off other treatments. The results move the company closer to seeking a launch for what could become the first cell therapy approved for an autoimmune condition.
9:52 AMStat News
An Indonesian court ruling challenges pharmaceutical patent evergreening, the practice of extending exclusivity through secondary patents or minor product changes. Patient advocates say the decision could encourage other countries to contest similar strategies.
10:57 AMStat NewsSummary
The United States is experiencing its worst measles outbreak since 1991, with the CDC recording a measles death and Pennsylvania officials reporting four deaths among unvaccinated people in recent weeks. The outbreak underscores the consequences of declining protection against a highly contagious disease.
Measles is again producing fatal outcomes in communities with insufficient vaccination coverage, turning a largely
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The outbreak will test whether public health authorities can restore vaccination coverage before transmission expands beyond unvaccinated communities.
Summary
Jewel Mullen recounts nearly dying from measles as a child in 1961 and describes her alarm at the disease's return. Writing as a physician, she connects that personal experience to the current erosion of confidence in measles vaccination.
Measles resurgence turns vaccine skepticism into a direct threat to children who cannot be protected
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Measles outbreaks are a visible measure of whether vaccination systems and public trust are holding.
Summary
FDA commissioner nominee Heidi Overton faced questions from senators about vaccines, abortion, and vapes during her confirmation hearing. She largely avoided revealing firm positions on the most politically contentious issues.
Overton's restraint limits the information senators and the public have about how she would use
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The FDA could soon be led by a commissioner whose governing approach remains unclear on several high-stakes public health issues.
Summary
Heidi Overton, President Trump's nominee to lead the FDA, built her career from a medical background in rural New Mexico to a national regulatory role. The profile examines her training, experience, and path to the nomination.
Overton's nomination would place someone with a distinctive personal and medical trajectory at the center
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The FDA commissioner shapes the standards that govern nearly every major medical product reaching patients.
Summary
Heidi Overton, President Trump's nominee to lead the FDA, is scheduled to answer questions from senators during her confirmation hearing. The hearing will examine her qualifications, policy views, and approach to running the agency.
The hearing will test whether Overton can explain how she would protect the FDA's scientific
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The confirmation process will signal how much scrutiny the FDA's next leader will face from Congress.
Summary
The report examines the expected start of Heidi Overton's tenure at the FDA and includes reporting from Shanghai. It combines U.S. regulatory developments with international healthcare and policy observations.
The immediate uncertainty around the Overton era is how the FDA will balance scientific standards
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Leadership changes at the FDA can alter the direction of drug, vaccine, and medical-device oversight well beyond the agency itself.
Summary
At a Senate hearing, FDA commissioner nominee Heidi Overton is expected to emphasize speed and efficiency as the agency competes with China. The hearing places regulatory performance and biotechnology competition at the center of her case for leading the agency.
The nomination is being framed around faster development and stronger competitiveness, which could increase pressure
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The next FDA leader could shape whether the agency pursues faster approvals through genuine modernization or through greater tolerance for regulatory risk.
Summary
AI tools that identify patients' secondary medical conditions added nearly $1 billion in costs for Blue Cross Blue Shield insurers over two years, according to a study from the Blue Cross Blue Shield Association. The findings focus on the financial impact of AI-assisted medical coding in provider claims.
The central shift is that AI coding is increasing insurer exposure rather than simply reducing
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
AI-assisted coding could raise premiums and public healthcare spending if insurers cannot verify whether added diagnoses reflect patients' actual conditions.
Summary
Researchers found that mammalian cells can produce the essential amino acid cysteine even after disabling pathways previously thought necessary for that process. The backup mechanism may help cancer cells survive treatment, making it a possible target for therapies designed to leave tumors unable to recover.
The crucial shift is that cells have more metabolic flexibility than standard pathway maps suggest.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
The pathway reveals a potential source of treatment resistance and a new vulnerability for cancer therapy.
Summary
Kyverna Therapeutics reported new data suggesting that many patients who received its cell therapy for an autoimmune disease remained off other treatments. The results move the company closer to seeking a launch for what could become the first cell therapy approved for an autoimmune condition.
The central development is durability: patients appear to maintain disease control without ongoing immunosuppressive therapy.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A durable autoimmune remission could create a new treatment category while forcing health systems to rethink how they pay for high-cost one-time therapies.
Summary
An Indonesian court ruling challenges pharmaceutical patent evergreening, the practice of extending exclusivity through secondary patents or minor product changes. Patient advocates say the decision could encourage other countries to contest similar strategies.
The ruling could narrow the period in which drugmakers can block generic competition after an
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A precedent against evergreening could accelerate generic entry and reduce the cost of medicines in markets where secondary patents delay competition.
A curated list of other prominent stories from this day.
Adarx Pharmaceuticals raised $446.3 million in an upsized US initial public offering, pricing shares at the top of its marketed range. The company is developing gene therapies and has programs in late-stage development.
7:43 PMBloomberg Markets
Radiology startups argue that owning clinical practices makes it easier to build and deploy AI tools directly into care. The coverage also examines insurer opposition to proposed changes involving remote patient monitoring.
9:21 AMStat News
Some radiology practices are developing and deploying artificial intelligence tools themselves rather than waiting for outside vendors. They are also branding their practices as AI-native organizations.
4:30 AMStat News
Researchers found that removing the protein NUDT5 protected cells from a decades-old leukemia drug, while simply blocking the protein did little. The result points to a previously unrecognized cellular role that may help explain differences in patients' treatment responses.
8:47 AMScienceDaily
Researchers identified a breakdown in communication between nerves and muscles that may contribute to age-related weakness. Targeting a key protein improved muscle strength in an animal model, suggesting a possible treatment path.
8:25 AMScienceDaily
Testing found live Legionella bacteria at seven sites in the South Bronx during an ongoing Legionnaires' disease outbreak. Results from three additional locations, including Yankee Stadium, remain pending.
7:00 AMGothamist
Gilead Sciences' executives are increasingly emphasizing the company's long-term effort to develop treatments for inflammatory and autoimmune diseases. The push represents a strategic expansion beyond the company's established strengths and reflects its ambition to build a larger immunology business.
6:30 AMStat News
A $499 medical checkup offered a firsthand look at how AI is being incorporated into healthcare. The experience examines what patients receive from high-cost, technology-heavy care and what that model suggests about the future of clinical assessment.
5:30 AMFortuneViolinist Jennifer Koh spent a decade trying to identify and treat a rare neurological disorder while continuing to perform. Her story follows the physical uncertainty behind a demanding career that often requires absolute control.
5:00 AMNew York Times Arts
Congress is considering the Patients First Act, which would link physician payment updates to medical inflation. The proposal would change how Medicare and potentially other payment systems account for rising practice costs.
4:30 AMStat News
President Trump and his aides claimed that every state wanted to join a federal drug-pricing initiative delivered through Medicaid. Several states said they had not decided whether to participate.
4:30 AMStat News
Cardiologist Vishal Khetpal argues that advances in the epidemiology and genetics of heart attack and stroke risk have outpaced the interventions currently available to act on that information. The essay questions what precision medicine can deliver when risk prediction exceeds treatment capability.
4:30 AMStat News
A large Danish study found that children diagnosed with ADHD or autism now resemble the broader child population more closely than those diagnosed a decade ago. The finding suggests that rising diagnosis rates partly reflect broader recognition and changing diagnostic practices, not necessarily a comparable rise in underlying conditions.
2:03 AMScienceDailySummary
Adarx Pharmaceuticals raised $446.3 million in an upsized US initial public offering, pricing shares at the top of its marketed range. The company is developing gene therapies and has programs in late-stage development.
Demand allowed Adarx to expand the offering and secure the maximum price it targeted, giving
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A strong IPO gives Adarx the resources to advance its therapies while offering a positive test of investor appetite for biotech companies with clinical and regulatory risk.
Summary
Radiology startups argue that owning clinical practices makes it easier to build and deploy AI tools directly into care. The coverage also examines insurer opposition to proposed changes involving remote patient monitoring.
The ownership model could give AI companies control over workflow, data, and implementation that vendors
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
AI in radiology may advance fastest where software firms control clinical operations, making ownership and payment policy as important as algorithm performance.
Summary
Some radiology practices are developing and deploying artificial intelligence tools themselves rather than waiting for outside vendors. They are also branding their practices as AI-native organizations.
Radiologists are moving from evaluating AI products to helping build and operationalize them, compressing the
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
AI may enter routine diagnosis faster when clinicians become developers, but the safeguards must keep pace.
Summary
Researchers found that removing the protein NUDT5 protected cells from a decades-old leukemia drug, while simply blocking the protein did little. The result points to a previously unrecognized cellular role that may help explain differences in patients' treatment responses.
The decisive finding is that NUDT5 appears to matter through its physical presence or broader
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A better explanation of the drug's mechanism could improve response prediction and revive new uses for an established leukemia treatment.
Summary
Researchers identified a breakdown in communication between nerves and muscles that may contribute to age-related weakness. Targeting a key protein improved muscle strength in an animal model, suggesting a possible treatment path.
The important shift is from treating muscle loss as a problem inside muscle tissue to
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
If the mechanism translates to humans, age-related weakness could become a treatable signaling disorder rather than an unavoidable consequence of aging.
Summary
Testing found live Legionella bacteria at seven sites in the South Bronx during an ongoing Legionnaires' disease outbreak. Results from three additional locations, including Yankee Stadium, remain pending.
The confirmed sites give health officials a defined set of locations to investigate and disinfect,
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Pending test results could determine whether the outbreak is contained or extends into higher-traffic areas.
Summary
Gilead Sciences' executives are increasingly emphasizing the company's long-term effort to develop treatments for inflammatory and autoimmune diseases. The push represents a strategic expansion beyond the company's established strengths and reflects its ambition to build a larger immunology business.
Gilead is signaling that immunology will be central to its next phase of growth, not
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Gilead's immunology bet will shape whether the company can replace growth from mature franchises with a broader pipeline.
Summary
A $499 medical checkup offered a firsthand look at how AI is being incorporated into healthcare. The experience examines what patients receive from high-cost, technology-heavy care and what that model suggests about the future of clinical assessment.
The key question is whether AI-powered checkups deliver better decisions or mainly package existing tests
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
AI's role in healthcare will be judged not only by accuracy but by whether it expands access or deepens the divide between premium and ordinary care.
Summary
Violinist Jennifer Koh spent a decade trying to identify and treat a rare neurological disorder while continuing to perform. Her story follows the physical uncertainty behind a demanding career that often requires absolute control.
For musicians, illness can threaten not just health but the basic mechanics of making a
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Her experience puts a human face on the hidden physical costs of an elite artistic career.
Summary
Congress is considering the Patients First Act, which would link physician payment updates to medical inflation. The proposal would change how Medicare and potentially other payment systems account for rising practice costs.
Indexing physician payments to medical inflation would replace a recurring political fight over annual updates
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
A new payment formula could reshape physician finances, Medicare spending, and access to care.
Summary
President Trump and his aides claimed that every state wanted to join a federal drug-pricing initiative delivered through Medicaid. Several states said they had not decided whether to participate.
The gap between the administration's claim and states' stated positions shows that the program lacks
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
State participation will determine whether the federal pricing initiative produces real savings or remains largely rhetorical.
Summary
Cardiologist Vishal Khetpal argues that advances in the epidemiology and genetics of heart attack and stroke risk have outpaced the interventions currently available to act on that information. The essay questions what precision medicine can deliver when risk prediction exceeds treatment capability.
Better genetic and epidemiologic prediction does not automatically produce better prevention, especially when clinicians lack
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Precision medicine will be judged by whether it changes cardiovascular outcomes, not merely by how accurately it predicts them.
Summary
A large Danish study found that children diagnosed with ADHD or autism now resemble the broader child population more closely than those diagnosed a decade ago. The finding suggests that rising diagnosis rates partly reflect broader recognition and changing diagnostic practices, not necessarily a comparable rise in underlying conditions.
The key shift is who gets identified, not simply how many children have these conditions.
Unlock the full First Pass Analysis to get a better understanding of why this story mattersWhy it matters
Diagnosis trends may be measuring changes in access and clinical thresholds as much as changes in childhood neurodevelopment.
Make it yours
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!